Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced favorable results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial, published in the New England Journal of Medicine. Children aged 2-5 using the t:slim X2 insulin pump with Control-IQ technology experienced an approximate 3-hour daily increase in time in range compared to standard insulin treatments. Key findings showed a 12.4% adjusted mean difference in time in range and a 0.5% decrease in Hemoglobin A1c levels. The trial included 101 participants, with 94% system usability, indicating significant improvements in glucose control.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Rebecca Robertson as Chair of its Board of Directors, effective immediately. Ms. Robertson, who joined the Board in January 2019, takes over from Kim Blickenstaff, who remains a Board member. The transition comes as the company seeks to enhance its leadership during a pivotal growth phase. CEO John Sheridan and Blickenstaff praised Robertson for her valuable insights and experience in medical devices. With a strong background in scaling medical companies, Robertson expressed her commitment to advancing Tandem's innovative solutions for diabetes care. The company continues to develop a promising product pipeline.

Tandem Diabetes Care (NASDAQ: TNDM) announced its financial results for Q4 and the full year 2022, highlighting a 14% increase in worldwide GAAP sales to $801.2 million and a 15% increase in non-GAAP sales to $804.8 million. The company reported a 29% growth in its customer base, totaling approximately 420,000. However, a GAAP operating loss of $92.8 million was noted for the year. In terms of guidance for 2023, TNDM expects non-GAAP sales between $885 million and $900 million, representing a growth of 10-12%. The firm also acquired AMF Medical SA, enhancing its product portfolio.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in several upcoming investor conferences. Key presentations will take place at the Citi Healthcare Services Conference on March 2, Cowen Healthcare Conference on March 6, Raymond James Conference on March 8, Oppenheimer Healthcare Conference on March 13, and Barclays Global Healthcare Conference on March 14. Each presentation will be webcast live, with an archive available for 30 days on their Investor Center website. Tandem Diabetes focuses on innovative insulin delivery solutions, including the t:slim X2 insulin pump.

Tandem Diabetes Care (NASDAQ:TNDM) has completed its acquisition of AMF Medical SA, the Swiss developer of the Sigi™ Patch Pump, which focuses on simplifying diabetes management. The Sigi Patch Pump is still under development and not yet commercially available. The acquisition aligns with Tandem's strategy to enhance its product offerings, bringing in AMF's innovative technology and experienced team. With a mission to improve diabetes care, Tandem aims to leverage this technology to better serve its customers.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its fourth quarter and full year 2022 financial results on February 22, 2023, after the market closes. A conference call is scheduled for 4:30 PM Eastern Time to discuss the results, which will be accessible via a webcast on their Investor Center website. The company emphasizes innovation in insulin delivery, particularly with its t:slim X2 insulin pump featuring Control-IQ technology, aimed at improving diabetes management. Further details will be available post-event on the website.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced its preliminary sales results for Q4 2022, reporting GAAP sales of $221 million, up from $210 million in Q4 2021. For the full year, GAAP sales reached $802 million, increasing from $703 million in 2021. The company expects a worldwide sales growth of 11-12% in 2023, not including new product launches like the Mobi Insulin Pump, under FDA review. The CEO highlighted strong customer retention and satisfaction for their t:slim X2 Insulin Pump.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The company will present an update on Wednesday, January 11, 2023, at 8:15 PM Eastern Time. The presentation will be available via a live webcast, with an archived recording accessible for 30 days on the company’s Investor Center website. Tandem Diabetes Care focuses on innovative insulin delivery solutions and is known for its t:slim X2 insulin pump featuring Control-IQ technology.

Tandem Diabetes Care (TNDM) has announced its definitive agreement to acquire AMF Medical, the Swiss developer of the Sigi™ Patch Pump. This acquisition is expected to expand Tandem's addressable market for insulin delivery solutions and enhance its product portfolio. The deal includes an initial payment of CHF 62.4 million, in addition to contingent earnout payments totaling up to CHF 129.6 million based on milestone achievements. The acquisition aims to accelerate product development, reduce waste, and offer additional customer access, with the transaction expected to close in January 2023.